You are here: Industry Insights > Skyhawk

News List

Aragen, Skyhawk partner to develop small molecule therapeutics that correct RNA expression expresspharma
July 16, 2021
Through this collaboration, Aragen will provide Skyhawk with various discovery chemistry and biology service solutions.
Skyhawk, Genentech Enter Exclusive Multi-target RNA Alliance contractpharma
July 17, 2019
Will leverage SkySTAR platform to discover and develop small molecule treatments for oncology and neurological disease targets.
Skyhawk, Biogen Expand Alliance in Neurological Disorders contractpharma
July 09, 2019
Skyhawk receives an upfront payment and is eligible for future milestones and royalties.
Skyhawk, Takeda to Develop Neurological Disease Targets contractpharma
May 16, 2019
Skyhawk will use its SkySTAR platform to discover and develop small molecule treatments.
Takeda taps Skyhawk's RNA-targeting tech for neurodegenerative disease fiercepharma
May 12, 2019
RNA biotech Skyhawk Therapeutics is inking another R&D deal—this time, it’s with Takeda Pharmaceutical, which wants to use the biotech’s platform to develop small molecules that correct RNA mis-splicing in neurodegenerative disease.
Skyhawk and Takeda partner to develop small molecule drugs pharmaceutical-technology
May 08, 2019
US-based Skyhawk Therapeutics has formed a strategic alliance with Takeda Pharmaceutical to discover and develop small molecule drug candidates for multiple targets across neurodegenerative diseases.
Skyhawk, Celgene in Strategic Discovery and Development Pact contractpharma
July 03, 2018
Skyhawk Therapeutics, Inc. has entered a global, five-year strategic collaboration with Celgene Corp. to discover, develop and commercialize innovative small molecule treatments for patients with neurological diseases based on Skyhawk's STAR technology pl
Celgene and Skyhawk initiate five-year collaboration for neurological diseases pharmaceutical-technology
June 28, 2018
Celgene has entered into a five-year global strategic collaboration with drug discovery and development company Skyhawk Therapeutics with an upfront payment of $60m